[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chlorhexidine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chlorhexidine":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,52,77,104,135],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100644051","oral-protect-i-oral-asepsis-preventing-transmission-during-intubation-100644051",false,"NCT07669064","ORAL-PROTECT I: Oral Asepsis Preventing Transmission During Intubation","ORAL-PROTECT I: Oral Asepsis for Preoperative Reduction Of Tracheal Bacterial Establishment, Colonization, and Transmission","ORAL-PROTECT I","Inclusion Criteria:\n\n* Age ≥ 60 years\n* Elective surgery under general anesthesia with endotracheal intubation\n* Expected duration of surgery ≥ 2 hours\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Systemic antibiotic therapy within 7 days before surgery\n* Planned postoperative systemic antibiotic therapy\n* Known hypersensitivity or allergy to chlorhexidine\n* Pneumonia or clinically relevant respiratory infection within 7 days before surgery\n* Inability to perform the study intervention as intended\n* Preoperative oral hygiene on the day of surgery, less than four hours prior to induction of the general anesthesia","ALL","60 Years",{"count":20,"type":21},60,"ESTIMATED","INTERVENTIONAL",[24],"NA","Postoperative respiratory complications, such as bacterial pneumonia, are common and serious problems after general anesthesia. They can lead to longer hospital stays, more complications, and increased mortality. One possible cause is that bacteria from the mouth and throat enter the lower airways during tracheal intubation.\n\nThe mouth and throat naturally contain many bacteria, including potentially harmful microorganisms. During general anesthesia, coughing and swallowing reflexes are reduced or absent. When a tracheal tube is inserted, secretions from the mouth and throat may be carried into the trachea. The tube may also support the movement of contaminated fluid into the lower airways.\n\nORAL-PROTECT I is a prospective, randomized, controlled study. It investigates whether simple oral hygiene before surgery can reduce the transfer of bacteria into the trachea during airway management under general anesthesia.\n\nThe study includes patients aged 60 years or older undergoing elective surgery under general anesthesia with tracheal intubation. Participants are randomly assigned to an intervention group or a control group. The intervention group performs oral hygiene immediately before anesthesia. This includes brushing the teeth and tongue for about 3 minutes, followed by rinsing and gargling for about 1 minute with a chlorhexidine antiseptic solution. The control group receives standard care without additional oral hygiene.\n\nOral, pharyngeal, and tracheal swabs will be collected at predefined time points. The primary outcome is based on the perioperative tracheal bacterial load, sampled every 30 minutes and assessed at two hours after induction of anesthesia. The co-primary outcome is based on the oral bacterial load immediately before endotracheal intubation.\n\nSecondary outcomes include changes in oral and tracheal bacterial load over time and identification of the microorganisms detected. The study aims to clarify early bacterial transfer during airway management and to evaluate whether a simple preoperative oral hygiene measure can reduce this process.",[27,28,29],"Bacterial Transmission","Intubation Intratracheal","Chlorhexidine",[31,32,33,34,35,36,37,38],"anesthesia, general","oral hygiene","bacterial load","oropharyngeal","respiratory mucosa","chlorhexidine","tracheal intubation","mouth rinsing","NOT_YET_RECRUITING","2026-06-21",{"date":42,"type":43},"2026-06-25","ACTUAL",{"date":45,"type":21},"2026-06-20",{"date":47,"type":21},"2027-05-01",{"name":49,"class":50},"University Hospital Ulm","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":4,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100644024","effects-of-chlorhexidine-on-human-gingival-fibroblasts-100644024","NCT07669636","Effects of Chlorhexidine on Human Gingival Fibroblasts","In Vitro Effects of a New Chlorhexidine-based Solution on Human Gingival Fibroblasts Survival and Function","Inclusion Criteria:\n\n* Male or female adults aged 18 years or older.\n* Undergoing routine dental surgical procedures (e.g., tooth extraction or gingivectomy).\n* Willing and able to provide written informed consent for the use of discarded gingival tissue for research purposes.\n* Systemically healthy.\n\nExclusion Criteria:\n\n* Presence of systemic diseases.\n* Presence of relevant medical comorbidities.\n* Current smoker.\n* Refusal to provide informed consent for the use of discarded biological material.",true,"18 Years",{"count":62,"type":21},3,"OBSERVATIONAL","This prospective in vitro study aims to evaluate the effects of two chlorhexidine-based mouthwash formulations on the survival and function of human gingival fibroblasts (hGFs). Gingival fibroblasts obtained from discarded gingival tissue collected during routine dental procedures will be cultured and exposed to different concentrations of a conventional 0.2% chlorhexidine mouthwash and a 0.2% chlorhexidine mouthwash supplemented with N-acetylcysteine (NAC) and hyaluronic acid (HA).\n\nCell viability, apoptosis, migration, and gene expression will be assessed at multiple time points using Trypan Blue exclusion assay, fluorescence-activated cell sorting (FACS), scratch assay, and quantitative real-time PCR. The study is designed to investigate the concentration-dependent effects of chlorhexidine on fibroblast viability and wound-healing-related functions and to determine whether the addition of NAC and HA may improve the biological compatibility of chlorhexidine-based formulations.",[66,67,29,68,69],"HGF","Fibroblast","Cytotoxicity","Biocompatibility",{"date":42,"type":43},{"date":72,"type":21},"2026-07-01",{"date":74,"type":21},"2026-11-01",{"name":76,"class":50},"IRCCS San Raffaele",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":22,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":51},"100582883","chlorhexidine-gluconate-versus-saline-for-flushing-the-surgical-area-during-colorectal-cancer-surgery-100582883","NCT06869096","Chlorhexidine Gluconate Versus Saline for Flushing the Surgical Area During Colorectal Cancer Surgery","A Comparative Study of Chlorhexidine Versus Saline Irrigation of the Surgical Area During Colorectal Cancer Surgery: a Multicenter, Stratified Randomized Controlled Trial.","Inclusion Criteria:\n\n1. Patients aged 18-85 years,\n2. Patients with surgically resectable colorectal tumors confirmed by CT\u002FMRI before surgery\n3. All patients had a performance status score of 0 or 1 in the Eastern Tumor Cooperative group\n4. American Society of Anesthesiology grade I-III\n\nExclusion Criteria:\n\n1. The tumor may have distant metastasis\n2. History of previous abdominal surgery\n3. The patient has a history of other malignant tumors diagnosed in the past 5 years and has received radiotherapy and chemotherapy in the past\n4. There are obvious contraindications to surgery (obvious abnormal liver and kidney function, pregnancy)\n5. Participated in other clinical trials within the past 6 months","85 Years",{"count":86,"type":21},532,[24],"The aim of this study was to compare the effectiveness of chlorhexidine versus saline in flushing the surgical area during colorectal cancer surgery. The primary outcomes included surgical site infection, postoperative complication rates, et al.",[90,91,29,92],"Colorectal Cancer","Surgical Site Infection","Complications","RECRUITING","2026-03-29",{"date":96,"type":43},"2026-03-31",{"date":98,"type":43},"2024-07-02",{"date":100,"type":21},"2026-12-31",{"name":102,"class":103},"Nanchong Central Hospital","OTHER_GOV",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":59,"sex":17,"minAge":60,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":116,"conditions":117,"keywords":121,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":51},"100623220","phase-3-evaluation-of-the-anti-plaque-effect-of-a-resveratrol-based-mouthwash-using-a-24-hour-plaque-re-growth-100623220","NCT07393802","Evaluation of the Anti-Plaque Effect of a Resveratrol-Based Mouthwash Using a 24-Hour Plaque Re-Growth","Evaluation of the Anti-Plaque Effect of a Resveratrol-Based Mouthwash Using a 24-Hour Plaque Biofilm Re-Growth Randomized Crossover Clinical Trial","Inclusion Criteria:\n\n* Age between 18 and 30 years\n* Systemically healthy individuals\n* Presence of at least 20 natural teeth\n* Clinically healthy gingiva with no signs of gingivitis or periodontitis\n* No probing depth \\>3 mm\n* No clinical attachment loss\n\nExclusion Criteria:\n\n* Presence of gingivitis or periodontitis\n* Active dental caries requiring treatment\n* History of periodontal therapy within the previous 6 months\n* Use of antibiotics, anti-inflammatory drugs, or antiseptic mouthwashes within the previous 3 months\n* Smoking or tobacco use\n* Pregnancy or lactation\n* Known allergy to any mouthwash components","25 Years",{"count":113,"type":21},20,[115],"PHASE3","Dental plaque is a biofilm that accumulates on tooth surfaces and is a primary factor in the development of gingival inflammation. While toothbrushing remains the main method for plaque control, the effectiveness of mechanical oral hygiene depends largely on individual compliance and technique. As a result, mouthwashes are commonly used as adjunctive chemical plaque control agents.\n\nChlorhexidine gluconate is an effective anti-plaque mouthwash, but its use is associated with undesirable effects that may limit patient acceptance. Resveratrol is a naturally derived compound with reported antimicrobial and anti-biofilm properties, suggesting its potential use as an alternative chemical plaque control agent.\n\nThis randomized, double-blind, placebo-controlled, three-period crossover clinical trial aims to evaluate the short-term anti-plaque effect of a resveratrol-based mouthwash by measuring supragingival plaque regrowth over a 24-hour period in periodontally healthy individuals. The effects of the resveratrol-based mouthwash will be compared with 0.12% chlorhexidine (CHX) and a placebo mouthwash under standardized conditions without mechanical oral hygiene",[118,29,119,120],"Mouthwash","Biofilm Formation","Periodontal Health",[122,123,124,125],"Resveratrol","mouthwash","anti-plaque","crossover","2026-01-30",{"date":128,"type":43},"2026-02-06",{"date":130,"type":21},"2026-03",{"date":132,"type":21},"2026-05",{"name":134,"class":50},"University of Baghdad",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":143,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100382220","phase-3-perioperative-respiratory-care-and-outcomes-for-patients-undergoing-high-risk-abdominal-surgery-100382220","NCT04256798","Perioperative Respiratory Care and Outcomes for Patients Undergoing High Risk Abdominal Surgery","PErioperative Respiratory Care and Outcomes for patieNts Undergoing hIgh Risk abdomiNal Surgery: A 2x2 Factorial, International Pragmatic Randomised Controlled Trial Across Low and Middle-income Countries","PENGUIN","Inclusion Criteria:\n\n* Adults and children aged 10 years or over\n* Elective or emergency abdominal surgery via midline laparotomy with an anticipated abdominal incision of at least 5cm in length\n* Written informed consent of patient (signature or a fingerprint)\n\nExclusion Criteria:\n\n* Patients undergoing caesarean section\n* Patients with a documented or suspected allergy to chlorhexidine\n* Patient unable to complete postoperative follow-up (not contactable after discharge)\n* Previous enrolment in PENGUIN within the past 30 days\n* American Society of Anesthesiologists (ASA) grade V patients (expected to die with or without surgery)","10 Years","100 Years",{"count":146,"type":21},12942,[115],"PENGUIN is a pragmatic multi-center trial investigating the effects of pre-operative mouthwash and perioperative oxygen on the incidences of pneumonia and surgical site infection (SSI) following major abdominal surgery.\n\nPatients will be recruited from low and middle income countries and randomly assigned to a trial treatment arms: a) pre-operative chlorhexidine mouthwash and 80-100% FiO2; b) no pre-operative mouthwash and 80-100% fraction of inspired oxygen (FiO2); c) pre-operative chlorhexidine mouthwash and 21- 30% FiO2; or d) no pre-operative mouthwash and 21-30% FiO2.",[150,151,91,152,153,154,155,156,157,158,29,159],"Infection","Pneumonia","Wound Infection","Surgical Wound Infection","Postoperative Complications","Anesthesia","Communicable Disease","Pathologic Processes","Perioperative Complication","Laparotomy","2025-02-18",{"date":162,"type":43},"2025-02-19",{"date":164,"type":43},"2020-11-13",{"date":166,"type":21},"2026-06-01",{"name":168,"class":50},"University of Birmingham",37]